CRNX Case Study: Action after FDA Approval
I first bought Crinetics Pharmaceuticals (CRNX) in June this year at an average cost of $31.86. From the start, it […]
CRNX Case Study: Action after FDA Approval Read Post »
Robinhood Gold & Roth IRA Match — Is It Worth It?
For years, I only associated Robinhood with its reputation for frequent trading and the meme-stock craze. It wasn’t a platform
Robinhood Gold & Roth IRA Match — Is It Worth It? Read Post »
Buy vs. Rent: Understanding Wealth Building in the Bay Area
I recently received an email from a real estate agent noting that housing prices in the Bay Area have increased
Buy vs. Rent: Understanding Wealth Building in the Bay Area Read Post »
New Release: A Smart Way to Maximize Roth with Variable Income
New Release: A Smart Way to Maximize Roth with Variable Income This Labor Day, I’m excited to share the release
New Release: A Smart Way to Maximize Roth with Variable Income Read Post »
The Cost of Chaos: What Struggling Families Reveal About Building Lasting Wealth
Introduction A recent Wall Street Journal article profiled two hard-working mothers navigating rising household costs while raising children on modest
The Cost of Chaos: What Struggling Families Reveal About Building Lasting Wealth Read Post »
Don’t Bet the Farm: Why Hero Trades Lead to Ruin
The Movie Myth That Won’t Die In Hollywood, going all-in is heroic. In The Big Short, Michael Burry bets billions
Don’t Bet the Farm: Why Hero Trades Lead to Ruin Read Post »
Reflection: Learning from Practical Leaders
Lately, I’ve found myself drawn to thinkers who value clarity and practicality over noise—people like William Bengen, Paul Merriman, and
Reflection: Learning from Practical Leaders Read Post »
How I Almost Lost a Piece of a Settlement (and Paid $200 for a $10 Form) — Lessons in Avoiding Financial Traps
By WealthPilot / Originally written on July 21, 2025 One day, while checking investment news on TradingView, I stumbled across
Rethinking the Small-Cap Premium in the Age of Private Markets
Over the past few weeks, I’ve been reflecting on a subtle but possibly significant structural shift in the investment landscape:
Rethinking the Small-Cap Premium in the Age of Private Markets Read Post »